{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:16:47Z","timestamp":1790414207092,"version":"4.1.0"},"reference-count":104,"publisher":"Informa Healthcare","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1517\/14656566.4.5.653","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T01:41:50Z","timestamp":1115257310000},"page":"653-666","source":"Crossref","is-referenced-by-count":36,"title":["Direct thrombin inhibitors"],"prefix":"10.1517","volume":"4","author":[{"given":"Karen L","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1146\/annurev.bi.57.070188.004411","volume":"57","author":"MANN KG","year":"1988","journal-title":"Ann. Rev Biochem."},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/216857a0","volume":"216","author":"DAVEY MG","year":"1967","journal-title":"Nature"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0021-9258(19)68276-1","volume":"257","author":"ESMON NL","year":"1982","journal-title":"?Biol. Chem."},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1016\/S0021-9258(18)83649-3","volume":"264","author":"ESMON CT","year":"1989","journal-title":"I Biol. Chem."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.270.24.14477","volume":"270","author":"BAJZAR L","year":"1995","journal-title":"?Biol. Chem."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/01.ATV.18.4.514","volume":"18","author":"COUGHLIN SR","year":"1998","journal-title":"Molecular mechanisms and roles in vivo. Arteriascier. Thromb. Vase. Biol."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","volume":"248","author":"ROSENBERG RD","year":"1973","journal-title":"?Biol. Chem."},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"WEITZ JI","year":"1997","journal-title":"N Engl. j Med."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","volume":"116","author":"CHOAY J","year":"1983","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"10421","DOI":"10.1016\/S0021-9258(19)86724-8","volume":"254","author":"LIU CY","year":"1979","journal-title":"?Biol. Chem."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","volume":"86","author":"WEITZ JI","year":"1990","journal-title":"?Chu. Invest."},{"key":"CIT0012","first-page":"220","volume":"102","author":"FRANCIS CW","year":"1983","journal-title":"GH etal.: Thrombin activity of fibrin thrombi and soluble plasmic derivatives. j Lab. Chu. Med."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1399-3011.1978.tb02889.x","volume":"12","author":"BAJUSZ S","year":"1978","journal-title":"Int. j Pep. Pro. Res."},{"key":"CIT0015","first-page":"277","volume":"249","author":"RYDEL TJ","year":"1990","journal-title":"TULINSKY A etal.: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(99)90018-8","volume":"13","author":"KAPLAN KL","year":"1999","journal-title":"Blood Rev"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0038-1651670","volume":"73","author":"AMIRAL J","year":"1995","journal-title":"Thromb. Haemost."},{"key":"CIT0019","first-page":"804","volume":"127","author":"WARKENTIN TE","year":"1997","journal-title":"HAYWARD CP etal.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med."},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0038-1649626","volume":"70","author":"MAGNANI HN","year":"1993","journal-title":"Thromb. Haemost."},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood.V51.6.1189.1189","volume":"51","author":"YUDELMAN IM","year":"1978","journal-title":"Blood"},{"key":"CIT0023","first-page":"506","volume":"20","author":"LINDER R","year":"1999","journal-title":"Netal.: The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease (Comment). Eur. Heart J."},{"key":"CIT0024","first-page":"751","volume":"57","author":"HAUPTMANN J","year":"2002","journal-title":"A review of small-molecule thrombin inhibitors. Eur. j Chu. Pharmacol"},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF01833843","volume":"18","author":"HAYCRAFT J","year":"1884","journal-title":"Arch. Exp. Path. Pharmak."},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1021\/bi00364a025","volume":"25","author":"STONE SR","year":"1986","journal-title":"Biochemistry"},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1021\/bi00389a004","volume":"26","author":"STONE SR","year":"1987","journal-title":"Biochemistry"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2007-998998","volume":"22","author":"TULINSKY A","year":"1996","journal-title":"Sem. Thromb. Hemost."},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/js980407q","volume":"88","author":"MEIRING S","year":"1999","journal-title":"?Pharm. Sci."},{"key":"CIT0030","first-page":"268","volume":"78","author":"MEYER BH","year":"1990","journal-title":"S. Air Med .j"},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02353540","volume":"22","author":"CARDOT J","year":"1994","journal-title":"?Pharmacokiriet. Biopharm."},{"issue":"88","key":"CIT0032","first-page":"2015\u2013","volume":"1993","author":"ZOLDHELYI P","year":"2022","journal-title":"Circulation"},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/0735-1097(93)90419-2","volume":"22","author":"VERSTRAETE M","year":"1993","journal-title":"j Am. Coll. Cardiol"},{"key":"CIT0034","first-page":"286","volume":"70","author":"TRIPODI A","year":"1993","journal-title":"ARBINI AA etal.: Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb. Haemost"},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0049-3848(97)00082-0","volume":"86","author":"POTZSCH B","year":"1997","journal-title":"Thrombosis Research"},{"key":"CIT0036","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/bj2960771","volume":"296","author":"BICHLER J","year":"1993","journal-title":"Biochem. j."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.1999.01532.x","volume":"106","author":"HUHLE G","year":"1999","journal-title":"Br. J. Haematol"},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/01.CIR.100.14.1528","volume":"100","author":"SONG X","year":"1999","journal-title":"Circulation"},{"key":"CIT0039","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1055\/s-0037-1615773","volume":"85","author":"HUHLE G","year":"2001","journal-title":"Thromb. Haemost."},{"key":"CIT0040","first-page":"2373","volume":"96","author":"EICHLER P","year":"2000","journal-title":"H-J,LUBENOW N et al.: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood"},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","volume":"29","author":"MARAGANORE JM","year":"1990","journal-title":"Biochemistry"},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1021\/bi00253a020","volume":"33","author":"PARRY MA","year":"1994","journal-title":"Biochemistry"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/bi00296a014","volume":"23","author":"KIKUMOTO R","year":"1984","journal-title":"Biochemistry"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","volume":"72","author":"BERRY CN","year":"1994","journal-title":"Thromb. Haemost."},{"key":"CIT0046","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood.V92.6.2064","volume":"92","author":"HANTGAN RR","year":"1998","journal-title":"Blood"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-2007-996128","volume":"23","author":"HURSTING MJ","year":"1997","journal-title":"Sem. Thromb. Hemost."},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003495-200161040-00005","volume":"61","author":"McKEAGE K","year":"2001","journal-title":"Drugs"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.318.34881"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0037-1614245","volume":"79","author":"GUSTAFSSON D","year":"1998","journal-title":"Thromb. Haemost."},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0037-1614477","volume":"81","author":"ERIKSSON H","year":"1999","journal-title":"Thromb. Haemost."},{"key":"CIT0053","first-page":"46a","volume":"98","author":"ERIKSSON UG","year":"2001","journal-title":"OHLSSON L et al.: The pharmacokinetics and pharmacodynamics of ximelagatran in patients with mild-to-moderate impairment of liver function. Blood"},{"key":"CIT0054","first-page":"45a","volume":"98","author":"SARICH TC","year":"2001","journal-title":"PETERS G etal.: Lack of effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran. Blood"},{"key":"CIT0055","first-page":"268a","volume":"98","author":"ERIKSSON UG","year":"2001","journal-title":"Blood"},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"P511","DOI":"10.1055\/s-0037-1616079","volume":"86","author":"LINDER R","year":"2001","journal-title":"Thromb. Haemost."},{"key":"CIT0058","first-page":"P3092","volume":"86","author":"ERIKSSON UG","year":"2001","journal-title":"Thromb. Haemost."},{"key":"CIT0059","first-page":"P3093","volume":"86","author":"ERIKSSON UG","year":"2001","journal-title":"Thromb. Haemost."},{"key":"CIT0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0049-3848(96)00230-7","volume":"85","author":"TEGER-NILSSON AC","year":"1997","journal-title":"Thromb. Res."},{"key":"CIT0061","first-page":"173","volume":"22","author":"SMITH GF","year":"1996","journal-title":"CRAFT TJ etal.: A family of arginal thrombin inhibitors related to efegatran.Sem. Thromb. Haemost."},{"key":"CIT0062","first-page":"71","volume":"277","author":"ROUX S","year":"1996","journal-title":"Pharm. Exp. Therapies"},{"key":"CIT0063","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.CIR.100.6.587","volume":"100","author":"GREINACHER A","year":"1999","journal-title":"Circulation"},{"key":"CIT0064","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.99.1.73","volume":"99","author":"GREINACHER A","year":"1999","journal-title":"Circulation"},{"issue":"103","key":"CIT0065","first-page":"1838\u2013","volume":"2001","author":"LEWIS B","year":"1843","journal-title":"Circulation"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ccd.10276","volume":"57","author":"LEWIS BE","year":"2002","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"CIT0067","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","volume":"96","author":"GREINACHER A","year":"2000","journal-title":"Blood"},{"key":"CIT0068","doi-asserted-by":"crossref","first-page":"501a","DOI":"10.1182\/blood-2001-12-0361","volume":"100","author":"LUBENOW N","year":"2002","journal-title":"Blood"},{"key":"CIT0069","first-page":"502a","volume":"100","author":"LUBENOW N","year":"2002","journal-title":"Blood"},{"key":"CIT0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1067\/mpd.2002.121384","volume":"140","author":"DEITCHER SR","year":"2002","journal-title":"J. Pediatr."},{"key":"CIT0071","first-page":"45a","volume":"98","author":"MATTHAI WJ","year":"2001","journal-title":"Blood"},{"key":"CIT0072","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.10181","volume":"71","author":"SMYTHE MA","year":"2002","journal-title":"Am. J. Hematol"},{"key":"CIT0073","first-page":"435","volume":"85","author":"SHETH SB","year":"2001","journal-title":"RA,HURSTING MJ etal.: Interpreting the International Normalized Ratio in individuals receiving argatroban and warfarin. Thromb. Haemost."},{"key":"CIT0074","first-page":"757","volume":"333","author":"SERRUYS PW HERRMAN J-PR","year":"1995","journal-title":"R etal.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl. J. Med."},{"key":"CIT0075","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","volume":"96","author":"Organization to assess strategies for ischemic syndromes","year":"1997","journal-title":"Circulation"},{"key":"CIT0076","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","volume":"353","author":"Organization to assess strategies for ischemic syndromes","year":"1999","journal-title":"Lancet"},{"key":"CIT0077","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","volume":"335","author":"The global use of strategies to open occluded coronary arteries","year":"1996","journal-title":"N Engl. J. Med."},{"key":"CIT0078","first-page":"1403","volume":"88","author":"ROE MT","year":"2001","journal-title":"PUMA JA etal.: Comparison of benefits and complications of Hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention (Brief Reports). Am. J. Cardiol"},{"key":"CIT0079","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/euhj.2001.2731","volume":"23","author":"MEHTA SR","year":"2001","journal-title":"Eur. Heart J."},{"key":"CIT0081","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","volume":"90","author":"NEUHAUS K-L, VON ESSEN R, TEBBE U et al.","year":"1994","journal-title":"Circulation"},{"key":"CIT0082","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","volume":"90","author":"The global use of strategies to open occluded coronary arteries","year":"1994","journal-title":"Circulation"},{"key":"CIT0083","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","volume":"94","author":"ANTMAN E","year":"1996","journal-title":"TIMI 9B Investigators. Circulation"},{"key":"CIT0084","first-page":"1493","volume":"31","author":"METZ BK","year":"1998","journal-title":"GRANGER CB etal.: Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from theGUSTO-IIb trial. JACC"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.5.1622"},{"key":"CIT0086","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","volume":"333","author":"BITTL JA","year":"1995","journal-title":"N Engl J. Med."},{"key":"CIT0087","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"LINCOFF AM","year":"2003","journal-title":"JAMA"},{"key":"CIT0088","first-page":"511","volume":"82","author":"BURCHENAL JE","year":"1998","journal-title":"TIFT MANN J et al.: Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am. J. Cardiol"},{"key":"CIT0094","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00019501-199609000-00009","volume":"7","author":"ANDERSEN K","year":"1996","journal-title":"Caron. Artery Dis."},{"key":"CIT0095","first-page":"1416","volume":"18","author":"A low molecular weight, selective thrombin inhibitor, inogatran, versus heparin, in unstable coronary artery disease in","year":"1997","journal-title":"A double-blind, randomized, dose-finding study. Thrombin Inhibition in myocardial ischaemia (TRIM) study group. Eur. Heart J."},{"key":"CIT0096","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1053\/euhj.1999.1477","volume":"20","author":"KLOOTWIJK P","year":"1999","journal-title":"Eur. Heart J."},{"key":"CIT0099","first-page":"294","volume":"359","author":"Direct thrombin inhibitors in acute coronary syndromes","year":"2002","journal-title":"Direct thrombin inhibitor trialists' collaborative group. Lancet"},{"key":"CIT0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0038-1648844","volume":"72","author":"ERIKSSON BI","year":"1994","journal-title":"Thromb. Haemost."},{"key":"CIT0102","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM199711063371901","volume":"337","author":"ERIKSSON BI","year":"1997","journal-title":"N. Eng] . J. Med."},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.5.2385"},{"key":"CIT0105","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/archinte.161.18.2215","volume":"161","author":"HEIT JA","year":"2001","journal-title":"Arch Int. Med"},{"key":"CIT0106","first-page":"231","volume":"87","author":"ERIKSSON BI ARFWIDSSON A-C","year":"2002","journal-title":"L etal.: A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb. Haemost."},{"key":"CIT0107","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(02)11469-3","volume":"360","author":"ERIKSSON BI","year":"2002","journal-title":"Lancet"},{"key":"CIT0108","first-page":"648","volume":"137","author":"FRANCIS CW","year":"2002","journal-title":"BERKOWITZ SD etal.: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med."},{"key":"CIT0109","first-page":"706a","volume":"98","author":"COLWELL CW","year":"2001","journal-title":"Blood"},{"key":"CIT0112","first-page":"1003","volume":"4","author":"HARENBERG J","year":"2002","journal-title":"Isr. Med Assn. 1"},{"key":"CIT0113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001721-199507000-00008","volume":"6","author":"KARIO K","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"CIT0114","first-page":"1033","volume":"30","author":"KARIO K","year":"1999","journal-title":"HOSHIDE S etal.: Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. Stroke"},{"key":"CIT0117","first-page":"123B","volume":"100","author":"HALPERIN JL","year":"2002","journal-title":"SPORTIF III and V investigators. Blood"},{"key":"CIT0118","first-page":"S41\u2013S45","volume":"72","author":"FRANK RD","year":"1999","journal-title":"STEFANIDIS I etal.: Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney InL"},{"key":"CIT0119","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0049-3848(00)00397-2","volume":"101","author":"ELG M","year":"2001","journal-title":"Thromb. Res."},{"key":"CIT0120","first-page":"P2614","volume":"86","author":"FAREED J","year":"2001","journal-title":"BENDER N etal.: Bleeding effects of antithrombin drugs can be neutralized by activated FVIIa (NovoSevenR) and combinations of otherplasma-derived products. Thromb. Haemost."},{"key":"CIT0121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0049-3848(00)00398-4","volume":"101","author":"ELG M","year":"2001","journal-title":"Thromb. Res."},{"key":"CIT0122","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-0038-1647455","volume":"65","author":"IBBOTSON SH","year":"1991","journal-title":"Thromb. Haemost."},{"key":"CIT0123","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001721-199306000-00011","volume":"4","author":"BUTLER KD","year":"1993","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"CIT0124","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0038-1650299","volume":"75","author":"BOVE CM","year":"1996","journal-title":"Thromb. Haemost."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.4.5.653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T15:55:44Z","timestamp":1625932544000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.4.5.653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":104,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,3,2]]},"published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1517\/14656566.4.5.653"],"URL":"https:\/\/doi.org\/10.1517\/14656566.4.5.653","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}